4.65
-0.06(-1.27%)
Currency In USD
| Previous Close | 4.71 |
| Open | 4.71 |
| Day High | 4.75 |
| Day Low | 4.62 |
| 52-Week High | 108 |
| 52-Week Low | 4.61 |
| Volume | 31,924 |
| Average Volume | 250,779 |
| Market Cap | 2.37M |
| PE | -0.2 |
| EPS | -23.7 |
| Moving Average 50 Days | 8.93 |
| Moving Average 200 Days | 16.34 |
| Change | -0.06 |
If you invested $1000 in Salarius Pharmaceuticals, Inc. (SLRX) 10 years ago, it would be worth $0 as of September 09, 2025 at a share price of $4.65. Whereas If you bought $1000 worth of Salarius Pharmaceuticals, Inc. (SLRX) shares 5 years ago, it would be worth $1.74 as of September 09, 2025 at a share price of $4.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
GlobeNewswire Inc.
Aug 14, 2025 12:30 PM GMT
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard
GlobeNewswire Inc.
Jul 14, 2025 12:30 PM GMT
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extensio
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
GlobeNewswire Inc.
Jul 09, 2025 12:30 PM GMT
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE)